Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 773

1.

Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.

Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.

Breast. 2013 Oct;22(5):958-63. doi: 10.1016/j.breast.2013.05.003. Epub 2013 Jun 10.

PMID:
23756383
2.

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.

PMID:
23414930
3.

18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.

Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.

J Nucl Med. 2012 Sep;53(9):1337-44. doi: 10.2967/jnumed.111.098640. Epub 2012 Jun 29.

4.

Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer.

Soussan M, Orlhac F, Boubaya M, Zelek L, Ziol M, Eder V, Buvat I.

PLoS One. 2014 Apr 10;9(4):e94017. doi: 10.1371/journal.pone.0094017. eCollection 2014.

6.

Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H.

Jpn J Clin Oncol. 2008 Apr;38(4):250-8. doi: 10.1093/jjco/hyn019.

7.

Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.

Nakajima N, Kataoka M, Sugawara Y, Ochi T, Kiyoto S, Ohsumi S, Mochizuki T.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):738-46. doi: 10.1016/j.ijrobp.2013.08.001. Epub 2013 Sep 21.

PMID:
24064322
8.

Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.

Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK.

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1534-43. doi: 10.1007/s00259-014-2744-4. Epub 2014 Mar 21.

PMID:
24652232
9.

Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.

Kim JY, Lee SH, Kim S, Kang T, Bae YT.

Eur Radiol. 2015 Apr;25(4):1172-81. doi: 10.1007/s00330-014-3452-y. Epub 2014 Oct 9.

PMID:
25298170
10.

Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.

Jo JE, Kim JY, Lee SH, Kim S, Kang T.

Acta Radiol. 2015 Dec;56(12):1463-70. doi: 10.1177/0284185114556929. Epub 2014 Nov 18.

PMID:
25406431
11.

Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.

Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P, Erkan ME, Halac M, Sonmezoglu K.

Nucl Med Commun. 2013 Nov;34(11):1055-67. doi: 10.1097/MNM.0b013e3283658369.

PMID:
24025919
12.

Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study.

Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M.

Breast Cancer Res Treat. 2013 Sep;141(2):269-75. doi: 10.1007/s10549-013-2687-7. Epub 2013 Sep 13.

13.

18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.

Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK.

Eur Radiol. 2014 Mar;24(3):610-8. doi: 10.1007/s00330-013-3037-1. Epub 2013 Oct 5.

PMID:
24097303
14.

Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.

Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K.

AJR Am J Roentgenol. 2014 Aug;203(2):272-9. doi: 10.2214/AJR.13.11971.

PMID:
25055259
15.

Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer.

Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK.

Eur Radiol. 2015 Nov;25(11):3314-21. doi: 10.1007/s00330-015-3734-z. Epub 2015 Apr 23.

PMID:
25903708
16.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.

Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.

17.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.

J Nucl Med. 2015 Jun;56(6):824-31. doi: 10.2967/jnumed.115.154138. Epub 2015 Apr 16.

18.

Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG.

Wang CL, MacDonald LR, Rogers JV, Aravkin A, Haseley DR, Beatty JD.

AJR Am J Roentgenol. 2011 Aug;197(2):W247-55. doi: 10.2214/AJR.11.6478.

PMID:
21785049
19.

Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.

Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J.

AJR Am J Roentgenol. 2015 Oct;205(4):878-85. doi: 10.2214/AJR.14.13906. Epub 2015 Jul 23.

PMID:
26204115
20.

Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.

Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.

Biomed Mater Eng. 2014;24(6):3091-103. doi: 10.3233/BME-141131.

PMID:
25227018
Items per page

Supplemental Content

Write to the Help Desk